This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 8 studies, archived under the term: "citalopram"

Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia

Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.; Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week […]

Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial

Objective: To determine the effect of discontinuing antidepressant treatment in people with dementia and neuropsychiatric symptoms.; Design: Double blind, randomised, parallel group, placebo controlled trial.; Setting: Norwegian nursing homes; residents recruited by 16 study centres in Norway from August 2008 to June 2010.; Participants: 128 patients with Alzheimer’s disease, dementia or vascular dementia, and neuropsychiatric […]

Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial

Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]

Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram

Background: This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial.; Methods: Forty family caregivers (43-91 years of age, 25 children and 15 spouses; 26 women) who were taking care of their relatives with Alzheimer […]

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms

The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial

Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]

Results of the citalopram to enhance cognition in Huntington disease trial

Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]

Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study

Background: Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer’s disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.; Methods: Inpatients with AD, who had been hospitalized because of […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: